Neuphoria Therapeutics (NASDAQ:NEUP) Given New $7.00 Price Target at HC Wainwright

Neuphoria Therapeutics (NASDAQ:NEUP) had its price objective lowered by HC Wainwright from $21.00 to $7.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 63.93% from the stock’s current price.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Maxim Group upped their price objective on Neuphoria Therapeutics from $18.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Finally, Weiss Ratings cut Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Neuphoria Therapeutics currently has an average rating of “Hold” and a consensus target price of $21.00.

Neuphoria Therapeutics Trading Up 1.9%

Shares of NEUP opened at $4.27 on Friday. The company’s 50 day simple moving average is $8.47 and its 200-day simple moving average is $8.37. The firm has a market cap of $22.96 million, a PE ratio of -0.88 and a beta of 0.51. Neuphoria Therapeutics has a 12-month low of $2.77 and a 12-month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings results on Friday, November 14th. The company reported ($4.41) EPS for the quarter, missing the consensus estimate of ($0.55) by ($3.86). As a group, equities research analysts forecast that Neuphoria Therapeutics will post -1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Neuphoria Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 639,110 shares of the business’s stock in a transaction dated Tuesday, October 21st. The stock was acquired at an average cost of $5.14 per share, with a total value of $3,285,025.40. Following the purchase, the insider owned 875,328 shares in the company, valued at approximately $4,499,185.92. This represents a 270.56% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Neuphoria Therapeutics

An institutional investor recently bought a new position in Neuphoria Therapeutics stock. Millennium Management LLC bought a new position in shares of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 18,329 shares of the company’s stock, valued at approximately $216,000. Millennium Management LLC owned approximately 0.78% of Neuphoria Therapeutics as of its most recent filing with the SEC. 15.90% of the stock is owned by institutional investors and hedge funds.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.